PrintPrint

Awards

Topic Information Award/Contract Number Proposal Information Company Performance
Period
Award/Contract
Value
Abstract

H-SB018.1-001
Development of a Wearable Fentanyl Analog Sensor

70RSAT18C00000032 FY18.1-H-SB018.1-001-0012-I
(FY18.1 Phase I)
Wearable Fentanyl Analog Sensor

Polestar Technologies, Inc.
220-3 Reservoir Street
Needham Heights, MA 02494-3133

05/02/2018
to
11/01/2018
$149,976.17

A Phase I SBIR is proposed for the development of a wearable sensor to protect law enforcement and first responders from inadvertent exposure to potentially toxic levels of fentanyl and/or fentanyl analogs. The Phase I project will demonstrate the ability of the new sensor to selectively detect the presence of fentanyl analog vapors from solid samples or air-borne particulates in concentrations below ECt50 levels. The work will focus on the development of a new selective fentanyl-binding polymer integrated into a chemical sensing antenna structure and the development of a preliminary design of a low-cost, low-power set of read electronics to use with the sensing antenna. Response data from tests of the sensing antenna against non-hazardous fentanyl analogs and common clutter agents including heroin and heroin cutting compounds will be used to show the feasibility of the new sensor. The new fentanyl analog sensor will have commercial application, not only in individual personnel safety, but also in facilities or event protection where aerosolized fentanyl and fentanyl analogs could be deployed as weapons. Further, modification of the fentanyl-binding polymer layer to enable selective binding of toxic industrial chemicals or volatile organic compounds could expand the commercial potential of the sensor to fire and mine safety, as well as hazmat applications.

H-SB018.1-001
Development of a Wearable Fentanyl Analog Sensor

70RSAT18C00000017 FY18.1-H-SB018.1-001-0015-I
(FY18.1 Phase I)
Rapid Tox-Based Wearable Sensing Badge for Solid Aerosol and Contact Exposure to Fentanyls

Nano Terra, Inc.
737 Concord Ave.
Cambridge, MA 02138-1002

05/02/2018
to
11/01/2018
$99,875.11

Nano Terra proposes to develop a low-cost and wearable detector badge that quickly and selec-tively alerts the user to the presence of solid fentanyl aerosols with an audible and visual alert. Current commercial fentanyl and opioid detectors are bulky and costly and have unsuitably-high limits of detection. Nano Terra will leverage their expertise in ultra-sensitive dosimetric detection of threat agents to advance their existing highly-selective opioid sensor for use in a compact wearable badge. The proposed system will be unobtrusive and inexpensive, while offering the necessary high sensitivity, high selectivity (distinguishes amongst fentanyl analogs and cutting agents), and rapid response time needed for the requirements of law enforcement and first responders. We will also develop and integrate a proof-of-concept toxicity-based sensor for opioids in which sensors are formulated to provide a real-time assessment of the effective human toxicity of operational environments containing multiple opioid species whose concentration or identity may not be known.

H-SB018.1-001
Development of a Wearable Fentanyl Analog Sensor

70RSAT19C00000009 FY18.1-H-SB018.1-001-0015-II
(FY18.1 Phase II)
Rapid Tox-Based Wearable Sensing Badge for Solid Aerosol and Contact Exposure to Fentanils

Nano Terra, Inc.
737 Concord Ave.
Cambridge, MA 02138-1002

04/01/2019
to
03/31/2021
$999,490.86

Clear Scientific, a wholly-owned subsidiary of Nano Terra, proposes to develop a low-cost and wearable detector badge that quickly alerts the user in real time to the presence of solid or aerosolized fentanils with an audible and visual alert. Current commercial opioid detectors are bulky, costly, and cannot be used passively in real time. Clear Scientific will leverage their expertise in ultra-sensitive dosimetric detection of threat agents to advance their highly-sensitive opioid sensor for use in a compact wearable badge. The proposed system will be unobtrusive and inexpensive, while offering the necessary high sensitivity, high selectivity (distinguishes amongst fentanyl analogs and cutting agents), and rapid response time needed for the requirements of law enforcement and first responders. The system will provide a real-time response based on the effective human toxicity of operational environments containing multiple opioid species whose concentration or identity may not be known.